APA (7th ed.) Citation

Li, Y., Chen, Y., Meng, Y., Shen, M., Yang, F., & Ren, X. Osimertinib exacerbates immune checkpoint inhibitor-related severe adverse events by activating the IL-6/JAK/STAT3 pathway in macrophages. China Anti-Cancer Association.

Chicago Style (17th ed.) Citation

Li, Yuan, Yanping Chen, Yuan Meng, Meng Shen, Fan Yang, and Xiubao Ren. Osimertinib Exacerbates Immune Checkpoint Inhibitor-related Severe Adverse Events by Activating the IL-6/JAK/STAT3 Pathway in Macrophages. China Anti-Cancer Association.

MLA (9th ed.) Citation

Li, Yuan, et al. Osimertinib Exacerbates Immune Checkpoint Inhibitor-related Severe Adverse Events by Activating the IL-6/JAK/STAT3 Pathway in Macrophages. China Anti-Cancer Association.